The Pharmacokinetics of ACNU in Patients with Malignant Brain Tumor


ACNU[l-(4-amino-2-methylpyrimidine-5-yl)-methyl-3-(2-chloroethyl)-3-nitroso-urea hydrochloride] is a water-solube nitrosourea anticancer agent which has been developed in Japan [1, 16]. It contains nitroso (-NO), alkyl (R-CH2-), and carbamoyl (R-N-CO) ligands in common with lipid-soluble nitrosoureas (NU), such as l-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (CCNU) [5, 6, 9, 15, 20], 1,3-bis(2-chloroethyl)-l -nitrosourea (BCNU) [2, 14, 19, 22], and l-(2-chloroethyl)-3-(4-methylcyclohexyl)-l-nitrosourea (Me-CCNU) [17, 18, 23] (Table 4.1).


Brain Tumor Malignant Brain Tumor Brain Tumor Patient Brain Tumor Tissue Transition Rate Constant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Arakawa M, Shimizu F, Okada N (1974) Effect of 1 -(4-amino-2-methyl pyrimidine-5-yl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride on leukemia L-1210. Jpn J Cancer Res 65:191Google Scholar
  2. 2.
    Bloom HJG (1975) Combined modality therapy for intracranial tumor. Cancer 35:111–120PubMedCrossRefGoogle Scholar
  3. 3.
    Dixon WJ (1975) BMD Biochemical computer program. University of California Press, Los AngelesGoogle Scholar
  4. 4.
    Fenstermacher JD, Jonson JA (1966) Filtration and reflection coefficients of the rabitt blood-brain barrier. J Physiol (Lond.) 211:341–346Google Scholar
  5. 5.
    Fewer D, Wilson CB, Boldrey EB, Enot JK (1972) Phase II study of CCNU (NSC 79037) in the treatment of brain tumors. Cancer Chemother Rep 56:421–427PubMedGoogle Scholar
  6. 6.
    Garret MJ, Hughes HJ, Ryall RDH (1974) CCNU in brain tumors. Clin Radiol 25:183–184CrossRefGoogle Scholar
  7. 7.
    Hanano M, Awatsu S (1970) The 2nd symposium of drug metabolism and toxicity, KyotoGoogle Scholar
  8. 8.
    Hansh C, Smith N, Engle R, Wood H (1972) Quantitative structure-activity relationships of antineoplastic drugs: nitrosoureas and triazenoimidazoles. Cancer Chemother Rep 56:443–456Google Scholar
  9. 9.
    Hoogstraten B, Gottlieb JA, Caoili E, Tucher WG, Talley RW, Haut A (1973) CCNU (NSU 79037) in the treatment of Cancer-Phase II study. Cancer 32:38–43PubMedCrossRefGoogle Scholar
  10. 10.
    Levin VA, Kabra P (1974) Effectiveness of the nitrosourea as a function of their lipid solubility in the chemotherapy of experimental rat brain tumors. Cancer Chemother Rep 58:787–792PubMedGoogle Scholar
  11. 11.
    Mellet LB (1977) Physicochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system. Cancer Treat Rep 61:527–531Google Scholar
  12. 12.
    Nakamura K, Asami M, Kawada K, Sasahara K (1977) Quantitative determination of ACNU (1 -(4-amino-2-methyl-5-pyrimidinyl)methyl-1 -(2-chloroethyl)-1 -nitrosourea hydrochloride), a new water-soluble anti-tumor nitrosourea, in biological fluids and tissues of patients by high-performance liquid chromatography: I. Analytical method and pharmacokinetics. Ann Rep Sankyo Res Lab 29:66–74Google Scholar
  13. 13.
    Rail DP, Zubrod CG (1962) Mechanisms of drug absorption and excretion: passage of drugs in and out of the central nervous system. Ann Rev Pharmacol 2: 109–128CrossRefGoogle Scholar
  14. 14.
    Rail DP, Ben M, McCarthy DM (1963) 1.3-bis- ß-chloroethyl-1 -nitrosourea (BCNU): Toxicity and intial cranial trial. Proc Am Ass Cancer Res 4:55Google Scholar
  15. 15.
    Rosenblum ML, Reynold AF Jr, Smith KA, et al. (1973) Chloroethyl-cyclo-hexyl-nitro-sourea (CCNU) in the treatment of malignant brain tumors. J Neurosurg 39:306–316PubMedCrossRefGoogle Scholar
  16. 16.
    Shimizu F, Arakawa M (1975) Effects of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride on lymphoid leukemia L-1210. Jpn J Cancer Res 66:149–154Google Scholar
  17. 17.
    Sponzo RW, DeVita VT, Oliverio VT (1973) Physiological disposition of CCNU and MeCCNU in man. Cancer 3:1154–1159CrossRefGoogle Scholar
  18. 18.
    Taylor SG, Nelson L, Baxter D, Rosembaum C (1975) Treatment of grade III and IV astrocytoma with dimethyl triazenoimidazole carboxamide (DTIC, NSC-45388) alone and in combination with CCNU (NSC-79037) or methyl CCNU (MeCCNU, NSC-95441). Cancer 36:1269–1276PubMedCrossRefGoogle Scholar
  19. 19.
    Walker MD, Hurwitz BS (1970) BCNU (1.3-Bis (2-chloroethyl)-1-nitrosourea: NSC-409962) in the treatment of malignant brain tumor—a preliminary report. Cancer Chemother Rep 54:264–271Google Scholar
  20. 20.
    Walker MD, Rosenblum ML, Smith KA, Reynolds AF Jr (1971) The treatment of brain tumor with l-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (CCNU). Proc Am Ass Cancer Res 12: 51Google Scholar
  21. 21.
    Walker MD, Hilton J (1976) Nitrosourea pharmacodynamics in relation to the central nervous system. Cancer Treat Rep 60:725–728PubMedGoogle Scholar
  22. 22.
    Wilson CB, Bordrey EB, Enot KJ (1970) 1.3-Bis (2-chloroethyl)-nitrosourea (NSC-409962) in the treatment of brain tumors. Cancer Chemother Rep 54:273–281PubMedGoogle Scholar
  23. 23.
    Young RC, Walker MD, Canellos GP, Schein PS, Chabner BA, DeVita VT (1973) Initial clinical trial with MeCCNU. Cancer 31:2264–2269CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1988

Authors and Affiliations

  • T. Mori

There are no affiliations available

Personalised recommendations